Across biopharma operations, reactive “run‑to‑failure” maintenance is one of the biggest hidden drivers of downtime, deviations, and escalating lifecycle cost. As the industry moves toward digital maturity, organizations are shifting…
Across biopharma operations, reactive “run‑to‑failure” maintenance is one of the biggest hidden drivers of downtime, deviations, and escalating lifecycle cost. As the industry moves toward digital maturity, organizations are shifting…